A5029162469- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Nanoplatforms for cancer theranostics
- Cardiac and Coronary Surgery Techniques
- vaccines and immunoinformatics approaches
- Cancer Research and Treatments
- Cervical Cancer and HPV Research
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Herpesvirus Infections and Treatments
- Animal Virus Infections Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis B Virus Studies
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Colorectal and Anal Carcinomas
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Systems, Economic Evaluations, Quality of Life
- Extracellular vesicles in disease
- Blood Coagulation and Thrombosis Mechanisms
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
Transgene (France)
2016-2025
Firalis (France)
2011-2015
Treatment of chronic hepatitis B (CHB) typically requires life-long administration drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity resolution infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase domains core surface antigen has shown immunogenicity antiviral effects in mice. We performed phase 1 clinical trial to assess safety explore early efficacy CHB patients. This randomized, double blind,...
Increasingly comprehensive characterization of cancer-associated genetic alterations has paved the way for development highly specific therapeutic vaccines. Predicting precisely binding and presentation peptides to major histocompatibility complex (MHC) alleles is an important step toward such therapies. Recent data suggest that both class I II epitopes are critical induction a sustained effective immune response. However, prediction performance MHC been limited compared I.We present...
Abstract Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites disease is a priority area for research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report results single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on success presurgical intravenous delivery viruses tumors....
<h3>Background</h3> Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival comparison that of treated with chemotherapy alone. Our study intended establish the association between vaccine-induced T responses against tumor associated antigens (TAA) targeted by vaccine. <h3>Method</h3> The TIME trial was placebo-controlled, randomized phase II...
Background Cancer is characterized by an accumulation of somatic mutations, which a significant subset can generate cancer-specific neoepitopes that are recognized autologous T cells. Such emerging as important targets for cancer immunotherapy, including personalized vaccination strategies. Methods We used whole-exome and RNA sequencing analysis to identify potential neoantigens patient with non-small cell lung cancer. Thereafter, we assessed the T-cell reactivity candidate using long...
Abstract Background: Effective treatment for patients with metastatic cancer is limited, particularly colorectal liver lesions (mCRC), where accessibility to numerous tumours essential favourable clinical outcomes. Oncolytic viruses (OVs) selectively replicate in cells; however, direct targeting of inaccessible limited when using conventional intravenous or intratumoural administration routes. Methods: We conducted a multi-centre, dose-escalation, phase I study vaccinia virus, TG6002, via...
<p>AEs summarized by relationship to grade.</p>
<p>AEs summarized by relationship to TG6002 and 5-FC.</p>
<p>Adaptive T-cell responses to treatment. function was assessed by ELISpot assay, which showed an IFNγ-release response CEA and TG6002. <b>A,</b> Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. <i>n</i> = 6 patients, sample availability–dependent. <b>B,</b> Representative examples from two patients showing BS samples, in triplicate, depicting <b>C</b> <b>D,</b> TCRβ...
<p>Immunophenotyping patient PBMCs</p>
<p>mRNA sequencing of patient PBMCs revealing clustering DEGs involved in immune activation and response pathways to treatment. <b>A,</b> The number upregulated ssDEGs the post-treatment samples relative pretreatment controls for days 2 15 post-infusion. <b>B,</b> Volcano plots three patients that highlight nine commonly expressed (red: downregulated DEGs, blue: black: nonsignificant changes green: specific highlighted ssDEGs). <b>C,</b> Cluster plot...
<p>Trial schema and sampling schedule. <b>A,</b> Trial depicting treatment schedule of two planned cycles IHA TG6002 oral 5-FC. <b>B,</b> Patient blood tissue samples taken at various time points prior to during treatment. Blood were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with <a...
<div>AbstractPurpose:<p>Effective treatment for patients with metastatic cancer is limited, particularly those colorectal liver lesions, in which accessibility to numerous tumors essential favorable clinical outcomes. Oncolytic viruses (OV) selectively replicate cells; however, direct targeting of inaccessible lesions limited when using conventional intravenous or intratumoral administration routes.</p>Patients and Methods:<p>We conducted a multicenter,...
<p>Detection of TG6002 in patient tumor biopsies. <b>A,</b> Table summary data collated from assays to detect the presence biopsies: qPCR and qRT-PCR viral nucleic acids, plaque assay replication-competent virus (infectious particles per biopsy), IHC determine protein, 5-FU (pg/mg) demonstrate transgene activity. Samples are designated as either positive or negative/below limit detection for each assay. <b>B,</b> Representative examples positively stained cells...
<p>Detection of TG6002, nAb, 5-FC, 5-FU, and F-BAL in plasma following treatment. <b>A,</b> Plasma samples analyzed by qPCR to detect TG6002 Values stated are the number copies per milliliter (c/mL). <b>B,</b> Serum nAb titers (IC50) for <i>n</i> = 15 patients, sample availability–dependent. * <i>P</i> < 0.05, paired <i>t</i> test. <b>C,</b> concentrations at day 8 treatment (<i>n</i> 13 patients),...
<p>Activation of patient peripheral immune responses following treatment. <b>A,</b> CRT concentration (ng/mL) in plasma measured by ELISA. Data are expressed as the mean ± SEM; <i>n</i> = 14 patients, sample availability–dependent. * <i>P</i> < 0.05, paired <i>t</i> test. <b>B,</b> Immunophenotyping PBMCs for expression CD69 and PD-L1. Relevant cell populations depicted each plot. fold change 9 patients....
TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. To support its development, preclinical experiments were performed either TG4010 or β-galactosidase-encoding MVA vector (MVA-βgal) mice presenting tumors the lung. Tumor growth was obtained after intravenous injection of CT26 murine colon cells, engineered to express MUC1 βgal....
6082 Background: Despite adjuvant therapy, over 50% of surgically treated head and neck squamous cell carcinoma (HNSCC) patients (pts) experience a recurrence disease. Systemic stimulation cellular immunity against tumor mutations using viral vaccine may be an ideal modality to clear residual cancer cells. For this purpose, we developed pipeline for the design TG4050, personalized (PCV) Modified Vaccinia Ankara (MVA) vector. We report here preliminary safety immunogenicity data from phase I...
Drug-induced vascular injury (DIVI) is a common preclinical toxicity usually characterized by hemorrhage, endothelial and smooth muscle damage, inflammation. DIVI findings can cause delays or termination of drug candidates due to low safety margins. The situation complicated the absence sensitive, noninvasive biomarkers for monitoring uncertain relevance humans. Safer And Faster Evidence-based Translation (SAFE-T) consortium public–private partnership funded within European Commission’s...